Adding the new calcium antagonist mibefradil to patients receiving long-term β-blocker therapy results in improved antianginal and antiischemic efficacy
Adam Schneeweiss, Isaac Kobrin, Vincent Charlon, Abraham Caspi, Alon Marmor, Samuel Sclarovsky, Leonardo Reisin, Zvi ZchlesingerVolume:
135
Year:
1998
Language:
english
DOI:
10.1016/s0002-8703(98)70093-6
File:
PDF, 139 KB
english, 1998